Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer 'in vivo'

Gene Therapy

Volumn 3, Issue 12, 1996, Pages 1151-1156

  Sacco, M G ^a   Benedetti, S ^b   Duflot Dancer, A ^c   Mesnil, M ^c   Bagnasco, L ^a   Strina, D ^a   Fasolo, V ^a   Villa, A ^a   Macchi, P ^a   Faranda, S ^a   Vezzoni, P ^a   Finocchiaro, G ^b  

^a CNR   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Breast tumors; Gap junctions; HSVtk ganciclovir; In vivo gene therapy; Neu oncogene; Retroviral vectors; transgenic mice

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER REGRESSION; CANCER THERAPY; CONTROLLED STUDY; FEMALE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; INTRATUMORAL DRUG ADMINISTRATION; LONG TERMINAL REPEAT; MALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; FEMALE; GANCICLOVIR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, ERBB-2; GENETIC VECTORS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; RATS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 12544260776     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300
2. Takamiyra Y et al. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes symplex virus type-I thymidine kinase gene and wild-type retrovirus kills other tumor cells. J Neurosci Res 1992; 33: 493-503.
3. Caruso M et al Regression of established macroscopic liver metastases after In situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
4. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256. 1550-1552
5. Culver KW, Blaese RM. Gene therapy for cancer. Trends Genet 1994; 10: 174-178.
6. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 1992; 339: 715-721.
7. Moolten FL. Tumor chemosensitivity conferred by insert herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
8. Borrelli E, Heyman R, Hsi M, Evans RM Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 1988; 85: 7572-7576.
9. Heyman RA et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci USA 1989; 86: 2698-2702.
10. Moolten FL, Wells JM, Heyman HA, Evans RM. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene Hum Gene Ther 1990; 1: 123-134.
11. Barba D, Hardin J, Sadelin M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors Proc Natl Acad Sci USA 1994; 91: 4348-4352.
12. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
13. Ram Z et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
14. Boviatsis EJ et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
15. Lucchini F et al. Early and multifocal rumors in breast, salivary, Harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett 1992; 64: 203-209.
16. Sacco MG et al. Local regression of breast tumors following intramammary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Gene Therapy 1995; 2: 493-497.
17. Colombo BM et al. The 'bystander effect': association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther 1995; 6: 763-772.
18. Mesnil M et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
19. Muller WJ et al. Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54: 105-115.
20. Cool V et al. Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum Gene Ther 1996; 7: 627-635.
21. Ram Z et al. Summary of results and conclusion of the gene therapy of malignant brain tumors: clinical study. J Neurosurg 1995; 82: 343A.
22. Li Bi W, Parysek LM, Warnick R, Stambrook PJ. In vivo evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
23. Elshami AA et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
24. Jou Y-S et al. Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 1995; 16: 311-317.
25. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
26. Guy CT et al. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992; 89: 10578-10582.
27. Chen S-H et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92. 2577-2581.
28. Deshane J et al. Targeted tumor killing via an intracellular antibody erbB-2. J Clin Invest 1995; 96: 2980-2989.
29. Hancock MC et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-4580.
30. Drebin JA et al. Downmodulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibody. Cell 1985; 41: 695-706.
31. Baum C et al. Gene transfer to augment the therapeutic index of anticancer chemotherapy Gene Therapy 1996; 3: 1-3.
32. Innis MA, Gelfand DH, Sninsky JJ, White TJ. PCR Protocols. A Guide to Methods and Applications. Academic Press, NY, 1990.